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Antimicrobial resistance was determined for 341 thermophilic Campylobacter jejuni
isolates obtained from human clinical cases (n = 101), broiler products (n = 98),
dairy cattle (n = 41) and wild birds (n = 101) with known multilocus sequence
types (MLST) in Lithuania. The minimum inhibitory concentration (MIC) values for
ciprofloxacin, tetracycline, gentamicin, ceftriaxone and erythromycin were determined
with the agar dilution method. MIC values were compared with MLST types to
find possible associations among isolation source, sequence type and resistance to
antibiotics. The proportions of resistant strains were 94.2% (human), 95% (wild birds),
100% (broiler products) and 100% (dairy cattle) for one of the tested antibiotics. Most
frequently, resistance to ciprofloxacin was observed (91.5%), followed by ceftriaxone
with 60.4%, and tetracycline (37.8%). However only three C. jejuni strains were resistant
to erythromycin (0.9%) and all tested thermophilic Campylobacter strains were sensitive
to gentamicin. Most of the examined C. jejuni isolates (80.6%) showed resistance to
at least one of three profiles: CIP+AXO (28.1%), TET+CIP+AXO (26.7%) and CIP
(25.8%). Statistically significant differences in resistance to tetracycline were found
between C. jejuni strains obtained from cattle (85.4%) and broiler products (64.3%)
(P < 0.05). The majority (87.1%) of the tested strains from wild birds were resistant
to ciprofloxacin (P < 0.05). The results showed that strains of novel ST’s showed
significantly lower resistance to ceftriaxone (P < 0.05). The ST-21 (CC21) (78.8%) was
identified with significantly higher multidrug resistance relatively to other tested ST’s in
this study. Our results emphasize the high antimicrobial resistance of phylogenetically
diverse C. jejuni strains isolated from different sources including specific genotypes
of wild bird’s strains in Lithuania. The results support the opinion that not only broiler
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products but cattle and wild birds may be a reservoir of resistant C. jejuni and stipulate
a risk of spread or resistant bacteria. There is increasing need for broad surveillance and
control measures to track changes and pathways of antimicrobial resistance of C. jejuni
in epidemiologically distinct populations.
Keywords: Campylobacter jejuni, MLST, antimicrobial resistance, multidrug resistance, humans, broiler, cattle,
wild birds
INTRODUCTION
Campylobacter spp. are zoonotic pathogens and a main
cause of human bacterial intestinal disease worldwide.
Thermophilic Campylobacter caused infection is one of the
most commonly reported foodborne zoonosis in the European
Union (EU) since 2005. The number of reported confirmed
cases of human campylobacteriosis was 246,307, with an EU
notification rate of 66.3 per 100,000 population (World Health
Organization [WHO], 2013; EFSA and ECDC, 2017). This
foodborne infection is primarily associated with consumption
of poultry products, followed by cattle associated food products
(French et al., 2009; de Haan et al., 2010; Mughini Gras
et al., 2012). The majority of foodborne infections caused by
thermophilic Campylobacter are mild and generally self-limited
within a few days without antimicrobial treatment. However,
complications can arise and may include bacteremia, Guillain-
Barre syndrome, reactive arthritis, and abortion (Skirrow and
Blaser, 2000). Usually, erythromycin (or other macrolides),
ciprofloxacin (fluoroquinolone) are used for the treatment
of human campylobacteriosis (Blaser and Engberg, 2008).
Fluoroquinolones are used widely for empirical treatment
for enteroinvasive bacterial diarrhea meanwhile the third-
generation cephalosporin’s like a ceftriaxone or gentamicin
(aminoglycoside) – for serious systematic infections. The
choice is based on the effective treatment option for common
human Campylobacter infection (Nahata and Barson, 1985;
Pacanowski et al., 2008; Ge et al., 2013). However, due to the
fact that in some countries extremely high acquired resistance to
fluoroquinolones is detected, it can no longer be considered for
empirical treatment of human Campylobacter infection (EFSA
and ECDC, 2018). Although tetracyclines are not often used in
practice, sometimes these antimicrobials could be considered as
an alternative choice in the therapy of Campylobacter infection
(Luangtongkum et al., 2009; Wieczorek and Osek, 2013).
However, thermophilic Campylobacter is becoming increasingly
resistant to antimicrobials used in clinical practices, and the
increasing resistance of these bacteria may have an adverse effect
on public health. Application of large amounts of antibiotics
for human therapy as well as for farm animals resulted in
the selection of pathogenic bacteria including thermophilic
Campylobacter resistant to multiple drugs (McDermott et al.,
2002; Luangtongkum et al., 2009; Juntunen et al., 2011). The
increasing resistance to antibiotics, particularly the high level of
ciprofloxacin-resistant thermophilic Campylobacter strains in
broilers, is a concern also in the EU (EFSA and ECDC, 2018).
The antimicrobial resistance of thermophilic Campylobacter
strains can be associated with specific isolation sources of
these bacteria. Thus, the high rate of resistant thermophilic
Campylobacter strains from wild birds indicate that this source
might be an important vector for the distribution of resistant
Campylobacter and the potential transfer to humans, cattle
and other sources.
The aim of this study was to investigate the phenotypic
antimicrobial resistance of C. jejuni strains in association
with MLST genotypes and isolation source (strains from




A total of 341 C. jejuni strains of known Multilocus sequence
types (MLST) were included in this study. The strain collection
was composed of 41 strains isolated from dairy cattle at farm
level, 98 strains isolated from retail broiler products, 101 strains
isolated from wild birds and 101 strains from human clinical
cases that were collected at the Microbiological Laboratory of
Kaunas Clinical Hospital over one year period. The MLST
method based on sequencing of seven housekeeping genes was
applied for each of the isolates as described in a previous
study (Ramonaite et al., 2014, 2017). The strains were stored at
−80◦C in brain heart infusion broth (BHI) (Oxoid, Basingstoke,
United Kingdom) with 30 % glycerol (Stanlab, Lublin, Poland).
Detection of Minimum Inhibitory
Concentration (MIC)
The C. jejuni strains were tested against phenotypic resistance
to five antimicrobial agents (ciprofloxacin, CIP, tetracycline,
TET, gentamicin, GEN, ceftriaxone, AXO and erythromycin,
ERY), (all Sigma-Aldrich, Saint-Louis, MO, United States) by
the agar dilution method according the Clinical and Laboratory
Standards Institute (CLSI) guidelines (CLSI, 2006). Mueller-
Hinton agar (Oxoid) with dilutions ranging from 0.25 to
256 mg/L for ciprofloxacin, tetracycline, gentamicin, ceftriaxone
and erythromycin was prepared. For each sample, 5 µl of
approximately 1×107 CFU/ml (OD600 = 0.1) bacterial suspension
dissolved in PBS (phosphate-buffered saline, Oxoid) was
spotted onto Mueller-Hinton agar containing the corresponding
antimicrobial agent and incubated at 37◦C for 48 h. The
experiment for all isolates was performed in triplicate. The MIC
values were defined as the lowest concentration that produces
complete inhibition of C. jejuni growth. For quality control, the
reference strain C. jejuni NCTC 11168 was included. Following
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MIC interpretive criteria for resistance were used: erythromycin
(≥32), tetracycline (≥16), ciprofloxacin (≥4), gentamicin (≥16)
and ceftriaxone (≥16) (CLSI, 2006). Isolates showing resistance
to three or more groups of antimicrobials were considered as
multidrug resistant (MDR).
Statistical Analysis
The statistical package SPSS (Statistics 20, IBM, Armonk, NY,
United States) was used for data processing and statistical
analysis. Chi-square test was used to test for statistically
significant associations between resistance to different
antimicrobial drugs and between resistance and MLST type. A P




Resistance to ciprofloxacin, tetracycline and ceftriaxone was
found in 91.5, 37.8, and 60.4%, of the tested C. jejuni strains,
respectively. Only three strains were resistant to erythromycin
with a MIC of 32 µg/mL (0.9%) and two of them were
isolated from humans (ST-5; ST-19) and one from wild birds
(ST-5843), respectively. Meanwhile, all C. jejuni strains were
sensitive to gentamicin. We identified ten C. jejuni specific
antimicrobial resistance profiles (Table 1) and most of the
examined C. jejuni strains (80.6%) showed resistance to one of
three profiles: CIP+AXO (28.1%), TET+CIP+AXO (26.7%) and
CIP (25.8%). The TET+CIP+AXO multidrug resistance profile
was confirmed for the majority of the examined C. jejuni strains
assigned to ST-21 (77.8%), ST-3098 (80%), ST-354 (100%), ST-
464 (53.3%), ST-6411 (66.7%), and ST-6391 (100%) Most of the
examined C. jejuni isolates which belonged to the ST-5 (75%)
were confirmed as CIP+AXO profile resistant (Figure 1 and
Supplementary Table S2).
Of the 341 tested C. jejuni strains, 330 (96.8%) were resistant
to at least one of the tested antimicrobials, whereas 11 strains
(3.2%) were sensitive to all five tested antibiotics. A total of
133 strains (39.0%) were resistant to two different classes of the
tested antibiotics and 93 strains (27.3%) were resistant to three
classes of antibiotics and were considered as multidrug resistant
(MDR) (Table 1).
All C. jejuni strains resistant to ciprofloxacin and ceftriaxone
showed high MICs (4-256, 16-128 µg/mL, respectively).
A significant percentage (51.1%) of tetracycline resistant strains
isolated from human clinical cases (77.3%), broiler products
(42.9%) and wild birds (44.5%) displayed a high-level resistance
with MIC values in the range from 64 up to 256 µg/mL (Table 2).
Among the 341 C. jejuni strains included in the antimicrobial
testing and MLST analysis, 146 distinct sequence types (STs) were
identified. Theses STs were assigned to 26 previously described
clonal complexes (CCs). In this study, 231 of C. jejuni strains
were included, which were grouped into previously known
sequence types (ST) and 110 isolates, which were assigned to
novel STs in a previous study (Ramonaite et al., 2014, 2017).
There were 110 (32.3%) C. jejuni strains representing 79 (54.1%)
STs that were previously described by our group as new STs.
Clonal complexes CC21 [50 (14.7%) strains], CC353 [42 (12.3%)
strains] and CC179 [26 (7.6%) strains] were dominant among
C. jejuni found among all tested sources and accounted for
34.6% of all strains. All ST-464 (CC464) C. jejuni strains were
resistant to tetracycline and ciprofloxacin (P < 0.05). This ST
was dominant among C. jejuni strains isolated from broiler
products. ST-5 (CC353) was dominant among C. jejuni strains
isolated from human clinical cases and 96.9% of these isolates
were resistance to ciprofloxacin and 84.4% showed resistance
to ceftriaxone. The results showed that strains belonged to ST-
21 (CC21) (77.8%) exhibited a significantly higher multidrug
resistance (P < 0.05). The results showed that strains belonging
to ST-21 (CC21) (94.4%), ST-257 (75%), ST-3098 (80%), ST-
353 (75%), and ST-354 (100%) were resistant to tetracycline.
ST-21 was dominant among dairy cattle in our study. Though,
some of the sequence types (ST-137, ST-2067, ST-354, ST-3546,
ST-356, ST-3573, ST-3755, ST-38, ST-446, ST-572, ST-6391, ST-
6409, ST-6412, ST-6413, ST-6433, ST-6784, ST-7207, ST-7309,
ST-7318, and ST-933) were not dominant in our study and all
strains assigned to these STs were MDR (Figure 1). Additionally,
C. jejuni sequence types assigned to CC1034 (100%), CC354
(81.8%), CC403 (100%), CC443 (55.6%), CC446 (66.7%), CC464
(53.3%) and CC61 (50%) showed high multidrug resistance
(Supplementary Table S1).
Antimicrobial Resistance of C. jejuni
Isolates From Human Clinical Cases
The lowest percentage of resistant C. jejuni strains isolated
from different sources was detected in humans (94.2%) and
resistance to CIP alone was the most frequently observed
(88.1%). Six C. jejuni (5.9%) strains isolated from human
clinical cases were sensitive for all tested antibiotics (Table 1).
Moreover, all strains isolated from human clinical cases were
sensitive to gentamicin. Only two strains (2%) were resistant
to erythromycin and these strains were assigned to ST-5
(CC353) and ST-19 (CC21). Most of the examined C. jejuni
strains from human clinical cases showed resistance to one
of two profiles: CIP+AXO (33.7%) and CIP (32.7%). The
ST-5 and ST-50, which are linked to CC353 and CC21,
were predominant among the C. jejuni strains isolated from
human clinical cases. ST-50 strains showed a 100% resistance
to ciprofloxacin and 100% were sensitive to erythromycin
and gentamicin. ST-5 strains showed a 95.7% resistance to
ciprofloxacin (Supplementary Tables S1, S2).
Antimicrobial Resistance of C. jejuni
Isolates From Broiler Products
All C. jejuni strains from broiler products were resistant
to at least one of our tested antibiotics. In total, 100%
of the tested strains were resistant to CIP. In addition, a
high number (71.4%) of ceftriaxone resistance strains was
detected. All C. jejuni strains from broiler products were
sensitive to erythromycin and gentamicin (Table 2). Most of
the examined C. jejuni strains isolated from broiler products
showed resistance to TET+CIP+AXO (42.9%) (Table 1). Three
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TABLE 1 | Antimicrobial resistance profiles of C. jejuni strains isolated from different sources.










Wild birds All tested
sources
N % N % N % N % N %
CIP+AXO 34 33.7 27 27.6 4 9.7 31 30.7 96 28.1
TET+CIP+AXO 8 7.9 42 42.9 33 80.5 8 7.9 91 26.7
CIP 33 32.7 7 7.1 – – 48 47.5 88 25.8
TET+CIP 12 11.9 21 21.4 – – – – 33 9.7
AXO 5 5 1 1 2 4.9 7 6.9 15 4.4
TET+AXO – – – – 2 4.9 1 1 3 0.9
TET+CIP+ERY 1 1 – – – – – – 1 0.3
CIP+AXO+ERY 1 1 – – – – – – 1 0.3
CIP+ERY – – – – – – 1 1 1 0.3
TET 1 1 – – – – – – 1 0.3
Total resistance 95 94.2 98 100 41 100 96 95 330 96.8
Sensitive 6 5.8 5 5 11 3.2
TET, tetracycline; ERY, erythromycin; CIP, ciprofloxacin; GEN, gentamicin; AXO, ceftriaxone.
FIGURE 1 | MLST profile and resistance profiles of C. jejuni sequence types
(STs) from human clinical cases, broiler products, dairy cattle and wild birds
from Lithuania (Detailed information on these MLST types is provided in
Supplementary Table S2).
STs (ST-5, ST-464 and ST-6410) were the most prevalent
among C. jejuni strains detected in broiler products. ST-
464 strains were 100% and ST-6410 strains were 81.8%
resistant to tetracycline. ST-5, ST-464 and ST-6410 were 100%
resistant to ciprofloxacin. ST-5 was 100% resistant to ceftriaxone
(Supplementary Table S1).
Antimicrobial Resistance of C. jejuni
Isolates From Dairy Cattle
All C. jejuni strains from dairy cattle were resistant to at
least one of our tested antibiotics. Ceftriaxone, ciprofloxacin
and tetracycline resistance was detected in 100, 90.2, and
85.4% of the tested dairy cattle strains, respectively. All
C. jejuni strains isolated from dairy cattle were sensitive
to erythromycin and gentamicin (Table 2). Most of the
examined C. jejuni strains from dairy cattle showed resistance
to TET+CIP+AXO (80.5%) (Table 1). CC21 and ST-21 were
predominant among C. jejuni strains detected in dairy cattle. All
ST-21 strains showed multidrug resistance to TET+CIP+AXO
(Supplementary Table S1).
Antimicrobial Resistance of C. jejuni
Isolates From Wild Birds
Altogether, 95% of the C. jejuni strains from wild birds were
resistant to at least one of the five tested antibiotics. The majority
of the tested strains (87.1%) were resistant to ciprofloxacin
(Table 2). Only one C. jejuni strain, isolated from wild birds,
was resistant to erythromycin and this strain was assigned
to ST-5843. All C. jejuni strains isolated from wild birds
were sensitive to gentamicin. Most of the examined C. jejuni
strains isolated from wild birds showed resistance to one of
two profiles: CIP+AXO (30.7%) and CIP (47.5%) (Table 1).
C. jejuni strains from wild birds showed lower multidrug
resistance (7.9%) and also lower resistance to tetracycline (8.9%)
in comparison to C. jejuni isolated from dairy cattle and broiler
products isolates.

























TABLE 2 | Minimum inhibitory concentration values for C. jejuni strains isolated from different sources against antimicrobial agents.






Antimicrobial agents MIC for C. jejuni isolates (MIC; µg/mL)




TET 79/78.2 22/21.8 41/40.6 32/31.7 5/5.0 1/1.0 5/5.0 10/9.9 4/4.0 3/3.0
ERY 99/98.0 2/2.0 16/15.8 54/53.5 28/27.7 1/1.0 2/2.0
CIP 12/11.9 89/88.1 2/2.0 10/9.9 3/3.0 40/39.6 27/26.7 17/16.8 2/2.0
GEN 101/100 0/0 21/20.8 69/68.3 8/7.9 3/3.0




TET 35/35.7 63/64.3 13/13.3 6/6.1 6/6.1 7/7.1 3/3.1 11/11.2 25/25.5 9/9.2 11/11.2 7/7.1
ERY 98/100 0/0 18/18.4 26/26.5 32/32.7 19/19.4 3/3.1
CIP 0/0 98/100 5/5.1 11/11.2 33/33.7 12/12.2 23/23.5 13/13.3 1/1.0
GEN 98/100 0/0 36/36.7 41/41.8 20/20.4 1/1.0




TET 6/14.6 35/85.4 4/9.8 1/2.4 1/2.4 3/7.3 6/14.6 22/53.7 4/9.8
ERY 41/100 0/0 1/2.4 11/26.8 15/36.6 7/17.1 5/12.2 1/2.4 1/2.4
CIP 4/9.8 37/90.2 4/9.8 2/4.9 6/14.6 18/43.9 7/17.1 1/2.4 3/7.3
GEN 41/100 0/0 18/43.9 21/51.2 2/4.9
AXO 0/0 41/100 20/48.8 15/36.6 4/9.8 2/4.9
Wild birds
(N = 101)
TET 92/91.1 9/8.9 44/43.6 6/5.9 25/24.8 9/8.9 8/7.9 1/1.0 4/4.0 1/1.0 3/3.0
ERY 100/99.0 1/1.0 51/50.5 11/10.9 32/31.7 3/3.0 3/3.0 1/1.0
CIP 13/12.9 88/87.1 13/12.9 47/46.5 27/26.7 12/11.9 2/2.0
GEN 101/100 0/0 36/35.6 42/41.6 20/19.8 2/2.0 1/1.0




TET 212/62.2 129/37.8 102/29.9 44/12.9 37/10.9 16/4.7 13/3.8 15/4.4 40/11.7 42/12.3 22/6.5 10/2.9
ERY 338/99.1 3/0.9 70/20.5 64/18.8 133/39.0 57/16.7 12/3.5 1/0.3 1/0.3 3/0.9
CIP 29/8.5 312/91.5 2/0.6 27/7.9 54/15.8 47/13.8 103/30.2 46/13.5 43/12.6 18/5.3 1/0.3
GEN 341/100 0/0 111/32.6 173/50.7 50/14.7 3/0.9 3/0.9 1/0.3
AXO 135/39.6 206/60.4 2/0.6 1/0.3 15/4.4 22/6.5 95/27.9 109/32.0 58/17.0 31/9.1 8/2.3
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DISCUSSION
Antimicrobial resistance, particularly multidrug resistance, is an
emerging and essential public health problem (Van Looveren
et al., 2001; Noormohamed and Fakhr, 2014). Zoonotic bacteria
that are resistant to antimicrobials are of particular concern, as
they might compromise the effective treatment of infections in
humans. This enabled analysis of multidrug resistance (MDR)
and co-resistance patterns to critically important antimicrobials
in both human and animal isolates at the EU level but
also at country level. Erythromycin resistance in thermophilic
Campylobacter is of public health significance, but occurs
at low, very low or undetected levels in many European
countries. Based on the ECDC report, the level of resistance
to erythromycin was overall relatively low (at 1.5%), but
varied between countries (ECDC, 2017). The low number
(0,9%) of erythromycin resistant C. jejuni strains found in
our study corresponds to reports from other countries such
as Finland (1,1%) (Lehtopolku et al., 2010), Italy (1,4%)
(Pezzotti et al., 2003) and Japan (0,6%) (Tadano et al., 1996).
Our results confirm that the level of erythromycin resistance
in Lithuania is low and stable and currently erythromycin
can be regarded as suitable drug for the treatment of
Campylobacter disease.
An increase in tetracycline resistance of C. jejuni strains
has been observed in recent years (Abdi-Hachesoo et al., 2014;
.ECDC, 2017). The number of tetracycline resistant C. jejuni
strains (37.8%) -irrespective of the source of isolation- found
in our study was at a similar level as in other countries
(Bywater, 2004; Gupta et al., 2004). In our study, a high-level
tetracycline resistance was found in C. jejuni strains isolated from
cattle (85.4%) and poultry products (64.3%) and this resistance
was significantly higher (P < 0.05) than resistance in C. jejuni
isolated from humans and wild birds. High rates of tetracycline
resistance might be due to the usage of this antibiotic as a
therapeutic agent in dairy cattle and poultry farms in our country
(Webb et al., 2018).
A high percentage of antimicrobial resistance (60.4%) of
C. jejuni to ceftriaxone was observed in our study. Interestingly,
those strains from wild birds showed a high percentage (46.5%)
of resistance to ceftriaxone, although wild birds do not have
contact with antimicrobial drugs. These findings suggest that the
resistance could be acquired by horizontal gene transfer or it
can also be related to migration of birds (Sjölund et al., 2008).
According to Auwera and Scorneaux (1985) and Hakanen et al.
(2003) C. jejuni is not susceptible to most cephalosporins, due to
alterations in the membrane structure or in porin proteins and
the eﬄux pump system can cause resistance to this antimicrobial
group (Lachance et al., 1991).
All C. jejuni strains were sensitive gentamicin in our
study. Aminoglycosides are effective in the treatment of
systemic thermophilic Campylobacter infections and in most
studies, resistance to gentamicin has also not been observed
(Sáenz et al., 2000).
Multidrug resistance of thermophilic Campylobacter strains
was defined as resistance to at least three different antimicrobial
classes (Magiorakos et al., 2012). We found that 27.3% of
all tested C. jejuni strains were MDR with the predominant
profile TET+CIP+AXO (26.7%). Moreover, this profile was
predominant among C. jejuni strains isolated from dairy cattle
(80.5%) and broiler products (42.9%). Additionally, we found
that 237 (69.5%) of the examined strains were resistant against
one or two antimicrobial agents and this percentage was higher
than that reported in a study from Denmark (Andersen et al.,
2006) and lower than that reported by a study in Poland
(Wieczorek et al., 2012).
We found significant differences in resistance to antimicrobial
agents among different thermophilic Campylobacter MLST
genotypes. ST-21 (CC21) was predominant among C. jejuni
strains isolated from dairy cattle in Lithuania. In total, 77.8%
of the strains assigned to ST-21 (CC21) and isolated from
dairy cattle were multidrug resistant (TET+CIP+AXO profile).
Meanwhile, ST-50 (CC21) was most often related with human
campylobacteriosis cases. Altogether, 54.5% of C. jejuni strains
assigned to ST-50 (CC21) and isolated from human clinical
cases were resistant to CIP and 27.3% to CIP and AXO.
An association between CC21 and quinolone resistance has
also been reported from Belgium (Habib et al., 2009) and
Slovenia (Kovacˇ et al., 2014) and resistance was observed
in 66 and 95% of the tested bacterial stains, respectively.
Strains of CC21, which have been associated with human and
dairy cattle antimicrobial resistance was not detected in wild
birds in this study.
The majority of C. jejuni strains from human and broiler
products were assigned to CC353 and ST-5 in our study
(Ragimbeau et al., 2008; Sheppard et al., 2009). In total,
75% of the C. jejuni strains assigned to ST-5 (CC353) and
isolated from broiler products and human clinical cases were
resistance to the CIP+AXO profile in our study (Iglesias-Torrens
et al., 2018). ST-464 (CC464) and ST-6410 were also often
assigned to C. jejuni strains isolated from broiler products.
We found that all (100 %) of the tested strains assigned
to CC464 and 97.6% of C. jejuni strains assigned to CC353
were resistant to ciprofloxacin (Cody et al., 2012). The same
resistance of C. jejuni to ciprofloxacin has been reported in
China (Zhang et al., 2016). Altogether, 61.5% of C. jejuni strains
isolated from broiler products and assigned to ST-464 (CC464),
45.5 and 36.4% strains assigned to ST-6410 (CC464) were
confirmed as TET+CIP+AXO, TET+CIP and TET+CIP+AXO
resistant profiles.
Our study revealed an unusually high number of ciprofloxacin
and ceftriaxone resistant C. jejuni strains isolated from humans,
broiler products, dairy cattle and wild birds. We observed
remarkably high resistance rates in C. jejuni from wild birds
too, although wild birds do not undergo treatment or have
direct contact with antimicrobial drugs. Interestingly, C. jejuni
strains assigned to novel MLST genotypes showed frequent
antibiotic resistance despite most of them were isolated from
wild birds. In addition, our study revealed significant resistance
to ciprofloxacin and tetracycline among C. jejuni assigned
to CC464. The unequal frequency of antibiotics resistant
strains between MLST clonal complexes and sequence types
indicates more common occurrence of resistance determinants
in some genotypes.
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In conclusion, the high antimicrobial resistance of
phylogenetically diverse C. jejuni strains isolated from different
sources including specific genotypes of wild bird’s strains in
Lithuania. The results of the study demonstrate that not only
broiler products but also cattle and wild birds may be a reservoir
for resistant C. jejuni and these reservoirs represent a risk to
spread resistant bacteria. These results suggest the need for broad
surveillance and control measures to track changes and pathways
of antimicrobial resistance of C. jejuni in epidemiologically
distinct populations.
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